Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

A new treatment being offered by High Plains Mental Health Center is proving to be life-changing for some people suffering ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

Nasal Spray Treating Major Depression Receives FDA Approval For Standalone Use The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...